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BACKGROUND:Many intracranial meningioma patients have an impaired health-related
quality of life (HRQoL) and neurocognitive functioning up to 4 yr after intervention.
OBJECTIVE: To assess the long-term (≥5 yr) disease burden of meningioma patients.
METHODS: In this multicenter cross-sectional study, patients ≥5 yr after intervention
(including active magnetic resonance imaging (MRI) surveillance) were included and
assessed for HRQoL (Short-FormHealth Survey 36), neurocognitive functioning (neuropsy-
chological assessment), anxiety and depression (Hospital Anxiety and Depression Scale),
and work productivity (Short Form-Health and Labour Questionnaire). Multivariable and
propensity score regression analyses were used to compare patients and controls, and
different treatment strategies corrected for possible confounders. Clinically relevant differ-
ences were reported.
RESULTS: At a median of 9 yr follow-up after intervention, meningioma patients (n= 190)
reported more limitations due to physical (difference 12.5 points, P = .008) and emotional
(13.3 points, P = .002) health problems compared with controls. Patients also had an
increased risk to suffer from anxiety (odds ratio [OR]: 2.6, 95% CI: 1.2-5.7) and depression
(OR: 3.7, 95% CI: 1.3-10.5). Neurocognitive deficits were found in 43% of patients. Although
postoperative complications, radiotherapy, and reresection were associated with worse
verbalmemory, attention, and executive functioningwhen compared to patients resected
once, the only clinically relevant associationwas between reresection andworse attention
(–2.11, 95% CI: –3.52 to –0.07). Patients of working age less often had a paid job (48%)
compared with the working-age Dutch population (72%) and reported more obstacles at
work compared with controls.
CONCLUSION: In the long term, a large proportion ofmeningioma patients have impaired
HRQoL, neurocognitive deficits, and high levels of anxiety or depression. Patients treated
with 1 resection have the best neurocognitive functioning.
KEYWORDS: Meningioma, Quality of life, Cognitive function, Anxiety, Depression
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M eningioma accounts for 37% of allprimary brain tumors.1-3 Morbidity ofintracranial meningiomas is primarily
due to compression of brain tissue and cranial
nerves, or treatment-related complications (eg,
ABBREVIATIONS: EORTC QLQ-BN20, European Organization for Research and Treatment of Cancer quality of life
questionnaire brain specificmodule;HADS,Hospital Anxiety and Depression Scale;HRQoL, health-related quality
of life; MAAS,Maastricht Aging Study; MCID,minimal clinically important differences;MRI,magnetic resonance
imaging; OR, odds ratio; SD, standard deviation; SF-HLQ, Short Form-Health and Labour Questionnaire; SF-36,
Short-Form Health Survey 36;WHO,World Health Organization
Supplemental digital content is available for this article at www.neurosurgery-online.com.
hemorrhage).3 Primary treatment for these
tumors consists of surgery, with in selected cases
first-line or adjuvant radiotherapy, resulting in a
10-year relative survival of 82% forWorldHealth
Organization (WHO) grade I meningioma.2,4,5
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One might expect that after decompression of central nervous
tissue, symptoms are resolved and functioning returns to normal
eventually. Historically, long-term meningioma survivors (≥5 yr
after intervention) who lived through the diagnosis and treatment
of a meningioma were often considered “cured.”3,6,7 However,
it is known from cancer populations that the experience of
living beyond tumor and treatment entails considerable lifelong
physical, cognitive, and psychological issues (eg, neurocognitive
impairments and disrupted social roles), which often differ from
the acute complications patients experience during diagnosis and
treatment (eg, impaired physical function due to paresis).8,9
Although it is known that surgery and radiotherapy might
improve health-related quality of life (HRQoL) and cognitive
function in the first year, recent studies have shown that up to a
median of 4 yr after intervention, meningioma patients may still
suffer from impaired HRQoL and neurocognitive functioning,
and increased anxiety and depression.7,10,11 Although data on
long-term effects of meningioma and its treatment on these
outcomes are lacking, studies in low-grade glioma suggest that
some impairments and deficits only manifest 5 yr beyond
treatment.12 Moreover, the impact on societal participation in
terms of work productivity is currently unknown.7
Thus, we aimed to assess the long-term (≥5 yr after their
intervention, ie, last antitumor treatment or initiation of active
magnetic resonance imaging [MRI] surveillance) disease burden
of meningioma patients in terms of HRQoL, anxiety and
depression, neurocognitive functioning, and work productivity.
We also assessed if these outcomes were affected by the type of
treatment received. Better knowledge of long-term survivorship
issues inmeningioma patients will help tomanage patients’ expec-
tations and design long-term meningioma care plans, tailored to
patient’s physical, psychological, and social needs.
METHODS
Participants
In this multicenter cross-sectional study, consecutive meningioma
patients were included if the end of the primary antitumor treatment
was at least 5 yr prior to recruitment, or in case of active MRI surveil-
lance, at least 5 yr after diagnosis. Eligible patients had to be 18 yr or
older, with a histologically confirmed WHO grade I or grade II menin-
gioma in case of surgery and an MRI-based clinically suspected menin-
gioma in case of radiotherapy or active MRI surveillance. Consecutive
patients were recruited from the neurosurgery, neurology, and radiation
oncology outpatient clinics of 2 academic hospitals and 1 large nonaca-
demic teaching hospital between July 2016 and April 2019. All eligible
patients were approached for this study via a letter signed by a member
of their treatment team. Patients were excluded if they had a history of
whole brain radiotherapy, were diagnosed with neurofibromatosis type
II or any neurodegenerative disease, or had insufficient mastery of the
Dutch language.
Informal caregivers of participating meningioma patients were
included for comparison of HRQoL, anxiety and depression, and work
productivity and were eligible for participation if they were a spouse,
family member, or close friend to the patient, 18 yr or older, and provided
the majority of emotional or physical support to the patient as reported
by the patient. It was not possible to include an informal caregiver for
every patient, as some patients were not able to identify an informal
caregiver motivated to participate in the study.
Procedures
This cross-sectional study was approved by the medical ethical
committees of all participating centers (NL54866.029.15), and partic-
ipants provided informed consent before study procedures. Both
questionnaires and neurocognitive assessment were administered once
on the same day, at least 5 yr after their last meningioma treatment.
Hence, there is variation in the follow-up length between patient’s last
meningioma treatment and moment of study participation. Clinical
information on tumor and treatment was obtained from the medical
records, while sociodemographic information about patients and controls
was obtained through a structured interview at the beginning of the
assessments.
Questionnaires
Patients completed questionnaires measuring HRQoL consisting of
the Short-Form Health Survey 36 (SF-36) and European Organization
for Research and Treatment of Cancer quality of life questionnaire, brain
specific module (EORTCQLQ-BN20). In addition, patients completed
the Hospital Anxiety and Depression Scale (HADS), and Short Form-
Health and Labour Questionnaire (SF-HLQ) measuring work produc-
tivity. Informal caregivers completed the same questionnaires, except for
the EORTC QLQ-BN20 (Supplemental Digital Content 1).
Neuropsychological Assessment
A comprehensive battery of neuropsychological tests was adminis-
tered by trained research nurses or research assistants and consisted of
the Auditory Verbal Learning Test, Concept Shifting Test, Memory
Comparison Test, Categoric Word Fluency Test, Digit-Symbol Substi-
tution Test, and the Stroop Color-Word Test. Based on these tests,
scores for the following neurocognitive domains were calculated:
executive functioning, verbal memory, working memory, psychomotor
functioning, information processing speed, and attention (Supple-
mental Digital Content 1).
Statistical Analysis
A description of the sample size calculation is provided in Supple-
mental Digital Content 2. SF-36 and EORTC QLQ-BN20 scores
were presented for each domain or scale/item, respectively, ranging from
0 to 100, with higher scores representing better HRQoL (SF-36), or
more symptomatology (QLQ-BN20). Total scores for both anxiety and
depression as measured with the HADS range from 0 to 21 and were
classified into no (scores: 0-7), borderline (scores: 8-10), and severe
anxiety or depression (scores: 11-21).13 Work productivity was measured
as having a paid job or not and experienced difficulties at work on 6
items.14 Unadjusted crude scores on the SF-36, EORTC QLQ-BN20,
and HADS for both patients and controls (ie, informal caregivers) are
presented in bar graphs.
Data on HRQoL (SF-36 only), anxiety and depression, and work
productivity were compared between meningioma patients and informal
caregivers, corrected for known confounders (ie, age, gender, education
level, and comorbidity) using multivariable regression analysis.10,12 As
a sensitivity analysis, data on HRQoL as measured with the SF-36 was
also compared between meningioma patients and published normative
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data using a one-sample t-test. For the EORTC QLQ-BN20 data,
we performed a one-sample t-test to compare meningioma data with
baseline data (ie, after surgery but before further antitumor treatment)
of glioblastoma patients from the AVAglio trial.15 This comparison with
the most common primary malignant brain tumor was done to put
disease-specific HRQoL into context. As minimal clinically important
differences (MCIDs) were not known for the used instruments in brain
tumor patients specifically, we used MCIDs previously established for
other patient groups. MCIDs was set on 10 points for scales/items of
the EORTC QLQ-BN20.16 Similarly, we set the MCID for the SF-36
domains also at 10 points, as the majority of reported MCID’s for the
different domains were<10 points.17 For the SF-36 mental and physical
component scales, MCIDs were set at 4.6 points and 3.0 points, resepec-
tively.18 Furthermore, for calculation of z-scores for each neurocognitive
domain, means and standard deviations (SDs) from a reference sample
from the Maastricht Aging Study (MAAS); large longitudinal study on
the psychological and biological determinants of cognitive aging) were
used, matched on group level for age, gender, and educational level.19
Per domain, differences in z-scores greater than –1.5 were considered
clinically relevant.20 In addition, meningioma patients of working age
were compared with net average working-age Dutch population (source:
Statistics Netherlands) for comparison of the percentage patients with a
paid job.21
The effects of surgery and radiotherapy were compared for those SF-
36 HRQoL and neurocognitive functioning domains on which patients
scored clinically relevant lower compared with controls, limiting the
number of statistical tests performed. Propensity score regression analysis
was used (see Supplemental Digital Content 2 for details) to adjust for
potentially relevant confounders (eg, age, tumor size, tumor location, and
Simpson grade).7,22
A nonresponders analysis was performed comparing important
clinical and sociodemographic characteristics between participating
meningioma patients and patients who chose not to participate. For all
statistical tests, SPSS 23 (IBM, Armonk, New York) was used, and P less
than .05 was considered statistically significant.
RESULTS
Demographics
A total of 190 patients (female: n = 149, 78%) were included
with a median follow-up since intervention of 9 yr (IQR: 7-
12 yr) (Table, Figure 1). Patients were on average 63 yr old (SD:
12). Tumors were located on the skull base in 92 patients (48%),
the cerebral convexity in 93 patients (49%), and the optic nerve
sheets or intraventricularly in 5 patients (3%). The majority of
surgically treated meningioma was classified as WHO grade I
(88%). Surgery was the primary choice of treatment in 168 (88%)
patients, of whom 63 suffered from any postoperative compli-
cation, such as cranial nerve deficits (n= 8) or cerebrospinal fluid
leak (n= 8). A total of 26 (14%) were treated with adjuvant radio-
therapy and 13 (7%) with reresection. Primary radiotherapy was
limited to 10 (5%) patients with anatomically complicated skull
base tumors. A total of 12 patients (6%) were solely followed
with active MRI surveillance without any antitumor treatment.
Patient- and tumor-related characteristics in each treatment group
are presented in Supplemental Digital Content 3. A total of 129
informal caregivers of participating meningioma patients were
included and data from 151 participants of the MAAS study.
Nonresponder analysis showed that participating and not partic-
ipating meningioma patients were similar on important sociode-
mographic and clinical characteristics, except for age, as not
participating patients were slightly older (Supplemental Digital
Content 4).
Health-Related Quality of Life (HRQoL)
After correction for confounders, patients had clinically
relevant lower HRQoL scores than controls on 2 of the
8 SF-36 domains: role limitations due to physical health problems
(corrected difference 12.5 points, P = .008), and role limita-
tions due to emotional health problems (13.3, P = .002). In
addition, they scored statistically significantly, but not clinically
relevant, lower on 2 additional domains and 1 component score:
social functioning (7.4, P = .008), vitality (7.1, P = .016), and
the mental component score (3.8, P = .005). No differences
were found for the other 4 domains and physical component
score (Figure 2). In the sensitivity analysis comparing menin-
gioma patients with normative data without correction for
confounders, patients had clinically relevant lower scores on 1
domain and 1 component score: role limitations due to physical
health problems (uncorrected difference 12.2, P < .001), and
the physical component score (5.0, P < .001). They scored
statistically significant, but not clinically relevant, lower on
3 additional domains: physical functioning (5.4, P = .004),
general health (7.2, P < .001), and social functioning (5.6,
P = .005) (Supplemental Digital Content 5). Comparing
meningioma patients with glioblastoma patients after surgery
but naive to chemotherapy and radiotherapy, we found that
meningioma patients had statistically similar scores on 4/11
EORTC QLQ-BN20 scales/items, showing impaired HRQoL:
visual disorder (difference: 2.5, P= .078), communication deficit
(–1.8, P = .291), headache (2.8, P = .296), and hair loss (2.3,
P = .101). The differences were not clinically relevant for these
scales/items or any of the other scales/items except future uncer-
tainty, for which glioblastoma patients reported more uncertainty
(Figure 3).
Anxiety and Depression
Patients sufferedmore frequently from borderline (8%, n= 15)
and severe (14%, n = 27) anxiety, compared with controls
(borderline: 6%, n = 8; severe: 3%, n = 4; overall P = .047,
Figure 4). Patients also suffered more frequently from borderline
(9%, n = 16) and severe (8%, n = 15) depression, compared
with controls (borderline: 3%, n = 4; severe: 2%, n = 2; overall
P = .099, Figure 4). Compared to controls, patients had an
increased risk to develop borderline or severe anxiety (odds ratio
(OR): 2.6, 95% CI: 1.2-5.7) and borderline or severe depression
(OR: 3.7, 95% CI: 1.3-10.5) after correction for confounders.
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TABLE. Sociodemographic and Clinical Characteristics of Meningioma Patients and Controls
Meningioma
patients n= 190
Informal caregivers
(n= 129)
MAAS controls
(n= 151)
Age, years 63 (SD 12) 61 (13) 60 (13)
Female 149 (78%) 47 (36%) 109 (72%)
Academic hospital 142 (75%)
Meningioma location
Skull base 92 (48%)
Convexity 93 (49%)
Other 5 (3%)
Symptoms of presentation (multiple options possible per patient)
Epilepsy 31 (16%)
Motor deficit 28 (15%)
Sensory deficit 24 (13%)
Visual deficit 51 (27%)
Cognitive impairment 14 (7%)
Headache 32 (17%)
Incidental finding 17 (9%)
Other 48 (26%)
Time since first symptoms, years 11 (9-14)
Time since diagnosis, years 10 (8-12)
Tumor size before intervention, mm 38 (26-50)
Tumor size before study, mm 0 (0-16)
Tumor growth on last MRI before study 10 (5%)
Number of meningiomas
≥2 26 (14%)
Active MRI surveillance 12 (6%)
Surgery as initial treatment 168 (88%)
Complication first surgery (operated patients: n = 168) 63 (38%)
Second surgery 13 (7%)
Third surgery 2 (1%)
Time since first surgery, years 9 (7-12)
Simpson grade (operated patients: n = 168)
Grade I-III 109 (65%)
Grade IV-V 40 (24%)
Unknown 19 (11%)
WHO grade (operated patients: n= 168)
Grade I 148 (88%)
Grade II 12 (7%)
Unknown 8 (5%)
Radiotherapy 36 (19%)
Radiotherapy as initial treatment 10 (5%)
Adjuvant radiotherapy 26 (14%)
Time since radiotherapy, years 8 (6-9)
Complications of radiotherapy (radiotherapy
treatment: n = 36)
3 (8%)
Karnofsky performance status at time of study 100 (90-100)
Self-reported cognitive deficit at time of study 94 (49%)
Self-reported motor deficit at time of study 55 (29%)
Seizures in the last 3 mo before study 8 (4%)
Antiepileptic drug use at any moment during the care
trajectory
90 (47%)
Dexamethasone use for symptoms at any moment
during the care trajectory
22 (12%)
Physical rehabilitation 37 (19%)
Cognitive rehabilitation 8 (4%)
Psychological support 21 (11%)
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TABLE. Continued
Meningioma
patients n= 190
Informal caregivers
(n= 129)
MAAS controls
(n= 151)
Other supportive care 10 (5%)
Education level
Primary/secondary 40 (21%) 14 (11%) 58 (38%)
Tertiary: technical/vocational 85 (45%) 55 (43%) 49 (32%)
Academic 59 (31%) 57 (44%) 45 (30%)
Not provided 6 (3%) 3 (2%)
Charlson Comorbidity Index
0 127 (67%) 88 (68%)
1≥ 63 (23%) 41 (32%)
Right-handed 147 (77%) 92 (71%)
Note. Informal caregivers and controls from the MAAS study.
FIGURE 1. Flowchart of patients and controls.
Neurocognitive Functioning
A total of 43% (n = 82) of patients suffered from a clinically
relevant neurocognitive deficit in at least 1 of the 6 measured
domains, most often in the domains of information processing
speed (n = 51, 27%) and attention (n = 44, 23%) (see
Figure 5 for all domains). Furthermore, 47 (25%) patients
suffered from a clinically relevant impairment in at least 2
domains, 32 (17%) patients in 3 domains, 22 (12%) patients in
4 domains, 20 (11%) patients in 4 domains, and 7 (4%) patients
in all 6 domains.
Work Productivity
Out of 190 meningioma patients, 123 (65%) were aged
between 18 yr and 67 yr and considered to be of working
age. At the time of assessment, 50% (62/123) of meningioma
patients had a paid job, compared with 72% of the net average
working-age Dutch population (P < .001). Reported reasons to
not have a paid job were being a homemaker (female patients
15%, male patients 0%) or poor health condition (both male
and female patients: 24%). More patients reported obstacles at
work (46%) than controls (17%, P = .005). The following
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FIGURE2. SF-36 health-related quality of life domain and component scores for both meningioma patients and controls, presented as bar charts and absolute
scores.
FIGURE 3. EORTC QLQ-BN20 scores for meningioma patients (median 9 yr after treatment) and for glioblastoma patients participating in the AVAglio
study at baseline (ie, comparison group for this analysis), presented as bar charts and absolute scores.
problems at work were reported to occur sometimes to always
(Figure 6): impaired concentration (74%), slower work pace
(78%), feeling isolated (22%), delaying work (67%), the need for
someone to take over their work (42%), and problems to make
decisions (59%).
Impact of Surgery and Radiotherapy on HRQoL and
Neurocognition
Patients treated with first line surgery or radiotherapy did
not score significantly different on HRQoL or neurocognitive
functioning compared to patients followed with active MRI
surveillance (Supplemental Digital Contents 6-11). However,
comparing surgery with radiotherapy as first-line treatment
showed that patients treated with radiotherapy scored signif-
icantly worse on verbal memory (–0.99, 95% CI –1.78 to
–0.20). Similarly, patients receiving additional radiotherapy after
surgery scored worse on verbal memory (–0.45, 95% CI −0.86
to −0.03) compared with patients solely treated by surgery.
Patients who suffered from a complication of their first surgery
scored worse on attention (−0.78, 95% CI −1.42 to −0.14)
compared with those without complications. Especially the need
for a second resection for residual tumor or recurrence resulted
in worse scores in executive functioning (−0.92, 95%CI −1.78
to −0.07), verbal memory (−0.66, 95%CI −1.25 to −0.08),
and attention (−2.11, 95%CI −3.52 to −0.71) compared with
patients who only needed a single resection. Except for attention
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FIGURE 4. Percentage of patients and controls with borderline or severe anxiety and depression as measured with the Hospital Anxiety and
Depression Scale.
FIGURE 5. Percentage of patients with a clinically relevant neurocognitive deficit (difference in z-score greater than –1.5
compared to the mean of controls), separately for each domain and in at least 1 domain.
in those patients needing a second resection, differences were not
clinically relevant.
DISCUSSION
Key Results
Although most meningioma patients have a benign WHO
grade I tumor with an associated near-normal life expectancy and
are often considered cured after intervention, our results show
firm evidence that patients still suffer from a significant disease
burden even after a median follow-up of 9 yr.Many patients suffer
from clinically relevant impaired HRQoL and neurocognitive
functioning, higher levels of anxiety and depression, and lower
levels of work productivity. The type of treatment also impacted
outcomes; patients who received 1 single resection had better
neurocognitive functioning compared with patients who experi-
enced surgical complications or were treated with (additional)
radiotherapy or who needed a reresection.
Limitations
Due to the observational cross-sectional design of this
study, no conclusions can be drawn on possible improvement
or deterioration after treatment and the results might suffer
from confounding and bias. Especially for the comparison
between patients treated with surgery or radiotherapy as first-line
treatment, selection bias might have affected the results, as radio-
therapy is often reserved for patients who are older, suffer from
comorbidities, or with a complicated anatomic tumor location.
To reduce the impact of confounding on our results, partic-
ularly when analyzing the cohort, we corrected our analyses
for multiple confounders using multivariable and propensity
scores regression analysis. Furthermore, we included a limited
number of patients with active MRI surveillance or radiotherapy
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FIGURE 6. Percentage of meningioma patients reporting difficulties with specific aspects of work.
as only treatment. Although radiotherapy is expected to have a
negative impact on outcomes in the long term, the number of
patients included with radiotherapy was too small to detect small
meaningful differences. In addition, we might miss meningioma-
specific HRQoL issues as we used the widely implemented SF-
36, which enabled comparisons with other patient groups. There
is no validated meningioma-specific HRQoL instrument that we
could have used.23 Moreover, as brain tumor-specific MCIDs are
not available for the questionnaires used, we used more conser-
vative MCIDs based on other patient populations. Hence, the
presented results might be on the more conservative side. Lastly,
we used both informal caregivers and normative data as controls
for HRQoL. As informal caregivers are indirectly affected by the
disease course of their loved ones but do not suffer directly from
the same physical and neurological consequences, we were able to
more accurately assess the impact of the tumor and its treatment.
Results of both comparisons were fairly similar, showing that
compared with informal caregivers or normative data, patients
scored clinically relevant lower on several domains/component
scores of the SF-36.
Interpretation
Existing frameworks for survivorship issues describe that while
in the acute phase of diagnosis and treatment, bodily impairments
can be expected, on the longer term patients primarily experience
disruptions of their social roles.7,9 Indeed, we found that patients
on the longer term reported clinically relevant more role limita-
tions due to physical and emotional health problems, whereas
previous studies reported impairments in cognitive and physical
functioning at a median of 6 mo and 4 yr after surgery.7,24
Remarkably, we found that patients with a benign meningioma
after long-term follow-up had similar HRQoL scores compared
with chemotherapy and radiotherapy naive glioblastoma patients.
Although the 2 groups are not comparable in terms of follow-up
length after treatment initiation, glioblastoma patients are often
considered having HRQoL impairments.25 To put the results in
context of major surgery in non-CNS related conditions, which
may also have a huge long-term impact on patients’ functioning
and well-being, meningioma patients reported lower physical
and mental HRQoL than similarly aged patients who received
coronary artery bypass graft surgery,26 and lower mental but
better physical HRQoL compared with patients who received
a total hip replacement.27 No neuropsychological impairments
in meningioma patients have been reported up to a median
of 3 yr after intervention.10,28 In low-grade glioma patients,
these deficits might only become apparent after more than
10 yr of follow-up.12 Indeed, we found that neurocognitive
deficits were present in over 40% of meningioma patients. The
limited published data on anxiety and depression describe that
approximately 10% to 15% of meningioma patients suffer from
severe depression or anxiety, respectively, both before and 6 mo
after surgery.11,29 It seems this percentage does not reduce over
time, as we found percentages of patients at risk for severe
depression or anxiety of 8% and 14%, respectively. Furthermore,
we found that patients less often have a paid job than the
age-matched Dutch population, because they were identified
as a homemaker (female patients 15%, male patients 0%) or
due to poor health condition (both male and female patients:
24%). Compared with patients with prolactinoma, another
benign intracranial lesion primarily affecting women, menin-
gioma patients of working age had less often a paid job (menin-
gioma patients: 50%; prolactinoma patients: 80%).27 Compa-
rably, female breast cancer patients do not have a paid job
due to their health issues and less often because they were
homemakers.28,29 Although not measured over time, we found
that patients who were treated by a single surgery reported
better HRQoL and neurocognitive functioning compared with
patients treated primarily with radiotherapy or additional radio-
therapy or reresection. Previous longitudinal studies in menin-
gioma patients reported improved but not normalized neurocog-
nitive functioning and HRQoL after surgery.28,30 Patients treated
with radiotherapy showed improvement in HRQoL in the first 6
mo after irradiation, with deterioration to preradiotherapy levels
after 2 yr.31 Only 1 (n = 18) study has compared the effects
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of postoperative radiotherapy in meningioma patents, reporting
no differences in HRQoL.32 However, the limited follow-up of
1 yr hampered assessment of possible long-term neurotoxicity of
radiotherapy.
Generalizability
We believe that our results are generalizable, as the number of
missing data was very limited (all assessments were performed
on a single day), patients were recruited from both academic
and nonacademic hospitals in the Netherlands, and because our
nonresponder analysis showed that our study population was
representative of the general meningioma population. General-
izability to other countries might be hampered due to differences
in health care settings and the impact of cultural differences on
outcomes such as HRQoL.
CONCLUSION
Although the continued improvement in surgical and radio-
therapeutic techniques for meningioma treatment has resulted in
an increase in long-term survivors, little was known about the
survivorship issues of these patients. The results of this study show
that the longer term disease burden is considerable. This infor-
mation is of importance to properly inform health care providers
and patients on the long-term sequelae of tumor and treatment.
This is relevant for proper expectation management, as well as
to develop care plans for long-term survivors, focusing on the
identified longer term impairments. Lastly, the results of this
study can be used as a benchmark for comparison of multiple
patient-centered outcomes in the long term when evaluating new
treatment modalities.33 Possible determinants for the long-term
disease burden are an important topic and should be explored in
more detail in future studies.
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resection.
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long-term effects of the treatment of intracranial meningioma so we can
better counsel and support our meningioma patients. Future papers will
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I n this multicenter cross-sectional study, 190 patients were studiedfor at least five years after surgery and radiotherapy for intracranial
meningiomas, including active MRI surveillance and serial assessment
of health related quality of life (SF-36), neurocognitive functioning
(neuropsychological assessment), anxiety and depression (HADS), and
work productivity (SF-HLQ). At a median of nine years follow-up after
intervention, patients reported more limitations due to physical and
emotional functioning compared with controls. Patients also had an
increased risk to suffer from anxiety and depression. Patients of working
age less often had a paid job compared to controls. This study serves as
an important reminder of the effect of meningioma treatment on quality
of life and the importance of initial treatments being successful and
durable given the finding that multiple treatments exert additive negative
effects on quality of life. These are important findings for neurosurgeons
treating meningioma patients.
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